homepage-top-section

The companies have signed a letter of intent to enter into collaboration for the development of a novel coronavirus vaccine by using their technologies. GSK CEO Emma Walmsley

As part of the deal, Alnylam will secure up to $2bn from Blackstone for the advancement of its RNAi medicines, which are believed to have the potential to

The clinical study, dubbed COLCORONA, will assess whether colchicine will serve as an effective treatment to prevent the phenomenon of major inflammatory storm present in adults suffering from

Under the binding agreement, the companies will work together to provide solutions for coronaviruses, including SARS-CoV-2, the novel coronavirus responsible for COVID-19. GSK will make an equity investment

Myelodysplastic syndromes are a group of closely related blood cancers characterised by ineffective production of healthy red blood cells, white blood cells and platelets, which may cause anaemia

Under an exclusive global licensing and research collaboration, the companies will involve in the assessment of up to four novel preclinical targets detected by Sitryx. The new targets

According to the company, the new programme is based on data showing that ST266 significantly decreased the inflammatory response of a body in a range of diseases and

The latest deal is said to leverage an existing agreement between the two companies established in 2018 for the development of mRNA vaccines for infectious diseases. Translate Bio

Under the deal, Vir can non-exclusively access Xencor’s Xtend Fc technology to expand the half-life of novel antibodies, which are being assessed as potential treatments for patients with